Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
Sven G. Meuth(University Hospital Münster), Steffen Pfeuffer(Justus-Liebig-Universität Gießen), Hagen B. Huttner(Universitätsklinikum Gießen und Marburg), Bruce Cree(University of California, San Francisco), Konstanze Kleinschnitz(University of Duisburg-Essen), Matthias Grothe(Universitätsmedizin Greifswald), S. Wolff(Justus-Liebig-Universität Gießen), Refik Pul, Tobias Bopp(Johannes Gutenberg University Mainz), Saskia Räuber(Düsseldorf University Hospital), Tobias Ruck(BG University Hospital Bergmannsheil Bochum), Kathrin Möllenhoff(University of Cologne), Hans‐Peter Hartung(The University of Sydney), Alice Willison(Düsseldorf University Hospital), Franz Felix Konen(Medizinische Hochschule Hannover), Anna Mück(Justus-Liebig-Universität Gießen), Thomas Skripuletz(Medizinische Hochschule Hannover), Marc Pawlitzki(Düsseldorf University Hospital), Christoph Kleinschnitz(Essen University Hospital)
Cited by 19
Related Papers
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k